Wallace Akerley is an Oncology physician affiliated with University of Utah. OpenAlex indexes 339 publications with 34,223 citations (h-index 47); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1950 Circle Of Hope
Clinic 1a
Salt Lake City, UT 841125500
Telephone
801-585-0100Provider last certified this registry record 16 Oct 2021.
Clinical trials
- A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer
Sponsor: University of Utah
- S0119: Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Sponsor: SWOG Cancer Research Network
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year20233 payments
- Eli Lilly and CompanyProgram year20231 payment
- Bristol Myers Squibb CompanyProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
2 NIH research awards on record, funded 2006–2025 per NIH RePORTER. The latest:
- Protocol Review and Monitoring System
Utah State Higher Education System--University of Utah
FY2025$275,703P30CA042014
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
Journal for ImmunoTherapy of Cancer
2022 - NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
Journal of the National Comprehensive Cancer Network
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Colman, MD
University of Utah
Michael Varner, MD
University of Utah
James Fang
University of Utah
Randall Burt, MD
University of Utah
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”